Antidiabetic drug use and prostate cancer risk in the Finnish Randomized Study of Screening for Prostate Cancer

References

• Bansal D, Bhansali A, Kapil G, Undela K, Tiwari P. Type 2 diabetes and risk of prostate cancer: a meta-analysis of observational studies. Prostate Cancer Prostatic Dis 2013;16:151–8.
   PubMed Web of Science ®Google Scholar
• Bensimon L, Yin H, Suissa S, Pollak MN, Azoulay L. Type 2 diabetes and the risk of mortality among patients with prostate cancer. Cancer Causes Control 2014;25:329–38.
   PubMed Web of Science ®Google Scholar
• Pierce BL. Why are diabetics at reduced risk for prostate cancer? A review of the epidemiologic evidence. Urol Oncol 2012;30:735–43.
   PubMed Web of Science ®Google Scholar
• Brown KA, Samarajeewa NU, Simpson ER. Endocrine-related cancers and the role of AMPK. Mol Cell Endocrinol 2013;366:170–9.
   PubMed Web of Science ®Google Scholar
• Stopsack KH, Ziehr DR, Rider JR, Giovannucci EL. Metformin and prostate cancer mortality: a meta-analysis. Cancer Causes Control 2016;27:105–13.
   PubMed Web of Science ®Google Scholar
• Kilpelainen TP, Tammela TL, Malila N, Kilpeläinen TP, Hakama M, Santti M, et al. Prostate cancer mortality in the Finnish randomized screening trial. J Natl Cancer Inst 2013;105:719–25.
   PubMedGoogle Scholar
• Teppo L, Pukkala E, Lehtonen M. Data quality and quality control of a population-based cancer registry. Experience in Finland. Acta Oncol 1994;33:365–9.
   PubMed Web of Science ®Google Scholar
• Sarre S, Määttänen L, Tammela TL, Auvinen A, Murtola TJ. Postscreening follow-up of the Finnish Prostate Cancer Screening Trial on putative prostate cancer risk factors: vitamin and mineral use, male pattern baldness, pubertal development and non-steroidal anti-inflammatory drug use. Scand J Urol 2016;50:267–73.
   PubMed Web of Science ®Google Scholar
• Martikainen J, Rajaniemi S. Drug reimbursement systems in EU member states, Iceland and Norway. Helsinki: The Social Insurance Institution, Social security and health reports 54. 2002. Available from: http://www.kela.fi/in/internet/english.nsf/NET/100203115310PN
   Google Scholar
• WHO Collaborating Centre for Drug Statistics Methodology [Internet]. Oslo: Norwegian Institute of Public Health. December 19, 2013. Available from: http://www.whocc.no/atc_ddd_index/
   Google Scholar
• Rosenbaum PR, Rubin DB. Reducing bias in observational studies using subclassification on the propensity score. J Am Stat Assoc 1984;79:516–24.
   Web of Science ®Google Scholar
• Kasper JS, Liu Y, Giovannucci E. Diabetes mellitus and risk of prostate cancer in the health professionals follow-up study. Int J Cancer 2009;124:1398–403.
   PubMed Web of Science ®Google Scholar
• Onitilo AA, Berg RL, Engel JM, Stankowski RV, Glurich I, Williams GM, Doi SAR. Prostate cancer risk in pre-diabetic men: a matched cohort study. Clin Med Res 2013;11:201–9.
   PubMedGoogle Scholar
• Benoit SR, Fleming R, Philis-Tsimikas A, Ji M. Predictors of glycemic control among patients with type 2 diabetes: a longitudinal study. BMC Public Health 2005;5:36.
   PubMed Web of Science ®Google Scholar
• Onitilo AA, Stankowski RV, Berg RL, Engel JM, Glurich I, Williams GM, Doi SA. Type 2 diabetes mellitus, glycemic control, and cancer risk. Eur J Cancer Prev 2014;23:134–40.
   PubMed Web of Science ®Google Scholar
• Hong SK, Oh JJ, Byun SS, Hwang S, Lee HJ, Choe G, Lee SE. Impact of diabetes mellitus on the detection of prostate cancer via contemporary multi (≥12)-core prostate biopsy. Prostate 2012;72:51–7.
   PubMed Web of Science ®Google Scholar
• Li Q, Kuriyama S, Kakizaki M, Yan H, Sone T, Nagai M, et al. History of diabetes mellitus and the risk of prostate cancer: the Ohsaki cohort study. Cancer Causes Control 2010;21:1025–32.
   PubMed Web of Science ®Google Scholar
• Moreira DM, Anderson T, Gerber L, Thomas J-A, Bañez LL, McKeever MG, et al. The association of diabetes mellitus and high-grade prostate cancer in a multiethnic biopsy series. Cancer Causes Control 2011;22:977–83.
   PubMed Web of Science ®Google Scholar
• Joentausta RM, Kujala PM, Visakorpi T, Tammela TL, Murtola TJ. Tumor features and survival after radical prostatectomy among antidiabetic drug users. Prostate Cancer Prostatic Dis 2016;19:367–73.
   PubMed Web of Science ®Google Scholar
• Gong Z, Neuhouser ML, Goodman PJ, Albanes D, Chi C, Hsing AW, et al. Obesity, diabetes, and risk of prostate cancer: results from the prostate cancer prevention trial. Cancer Epidemiol Biomarkers Prev 2006;15:1977–83.
   PubMed Web of Science ®Google Scholar
• Turner EL, Lane JA, Donovan JL, Davis MJ, Metcalfe C, Neal DE, et al. Association of diabetes mellitus with prostate cancer: nested case-control study (prostate testing for cancer and treatment study). Int J Cancer 2011;128:440–6.
   PubMed Web of Science ®Google Scholar
• Wu C, Aronson WJ, Terris MK, Presti JC, Kane CJ, Amling CL, Freedland SJ. Diabetes predicts metastasis after radical prostatectomy in obese men: results from the SEARCH database. BJU Int 2013;111:E310–18.
   PubMed Web of Science ®Google Scholar
• Fukushima H, Masuda H, Kawakami S, Ito M, Sakura M, Numao N, et al. Effect of diabetes mellitus on high-grade prostate cancer detection among Japanese obese patients with prostate-specific antigen less than 10 ng/mL. Urology 2012;79:1329–34.
   PubMed Web of Science ®Google Scholar
• Preston MA, Riis AH, Ehrenstein V, Breau RH, Batista JL, Olumi AF, et al. Metformin use and prostate cancer risk. Eur Urol 2014;66:1012–20.
   PubMed Web of Science ®Google Scholar
• Azoulay L, Dell'Aniello S, Gagnon B, Pollak M, Suissa S. Metformin and the incidence of prostate cancer in patients with type 2 diabetes. Cancer Epidemiol Biomarkers Prev 2011;20:337–44.
   PubMed Web of Science ®Google Scholar
• Suissa S, Azoulay L. Metformin and the risk of cancer: time-related biases in observational studies. Diabetes Care 2012;35:2665–73.
   PubMed Web of Science ®Google Scholar
• Margel D, Urbach D, Lipscombe LL, Bell CM, Kulkarni G, Austin PC, Fleshner N. Association between metformin use and risk of prostate cancer and its grade. J Natl Cancer Inst 2013;105:1123–31.
   PubMedGoogle Scholar
• Soranna D, Scotti L, Zambon A, Bosetti C, Grassi G, Catapano A, et al. Cancer risk associated with use of metformin and sulfonylurea in type 2 diabetes: a meta-analysis. Oncologist 2012;17:813–22.
   PubMed Web of Science ®Google Scholar
• Qiu H, Rhoads GG, Berlin JA, Marcella SW, Demissie K. Initial metformin or sulphonylurea exposure and cancer occurrence among patients with type 2 diabetes mellitus. Diabetes Obes Metab 2013;15:349–57.
   PubMed Web of Science ®Google Scholar
• Kuntz S, Mazerbourg S, Boisbrun M, Cerella C, Diederich M, Grillier-Vuissoz I, Flament S. Energy restriction mimetic agents to target cancer cells: comparison between 2-deoxyglucose and thiazolidinediones. Biochem Pharmacol 2014;92:102–11.
   PubMed Web of Science ®Google Scholar
• Bosetti C, Rosato V, Buniato D, Zambon A, La Vecchia C, Corrao G. Cancer risk for patients using thiazolidinediones for type 2 diabetes: a meta-analysis. Oncologist 2013;18:148–56.
   PubMed Web of Science ®Google Scholar
• Karlstad O, Starup-Linde J, Vestergaard P, Hjellvik V, Bazelier MT, Schmidt MK, et al. Use of insulin and insulin analogs and risk of cancer: systematic review and meta-analysis of observational studies. Curr Drug Saf 2013;8:333–48.
   PubMedGoogle Scholar
• Sciacca L, Vigneri R, Tumminia A, Frasca F, Squatrito S, Frittitta L, Vigneri P. Clinical and molecular mechanisms favoring cancer initiation and progression in diabetic patients. Nutr Metab Cardiovasc Dis 2013;23:808–15.
   PubMed Web of Science ®Google Scholar